Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group
Background Sorafenib is an oral small molecule inhibitor of multiple kinases controlling tumor growth and angiogenesis. The purpose of the phase 2 study was to determine the response rate of sorafenib and gain further information on the associated toxicities, pharmacokinetics, and pharmacodynamics o...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | 英语 |
| 出版: |
2015
|
| 在線閱讀: | https://doi.org/10.1002/pbc.25548 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|